Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Coal tar solution 3% in Betamethasone valerate 0.025% oint
1304000F0AAEEEE
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | No data available |
|
Coal tar solution 3% in Clobetasone 0.05% cream
1304000H0AACFCF
|
Clobetasone butyrate (Topical) | Clobetasone butyrate | Skin | No data available |
|
Coal tar solution 3% in Clobetasone 0.05% ointment
1304000H0AACSCS
|
Clobetasone butyrate (Topical) | Clobetasone butyrate | Skin | No data available |
|
Coal tar solution 3% in Yellow soft paraffin
1305020C0AAENEN
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar solution 5% in Aqueous cream
1305020C0AAFXFX
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar solution 5% in Betamethasone valerate 0.1% ointment
1304000F0AADGDG
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | No data available |
|
Coal tar solution 5% in Clobetasol 0.05% cream
1304000G0AACHCH
|
Clobetasol propionate | Clobetasol propionate | Skin | No data available |
|
Coal tar solution 5% in Clobetasol 0.05% ointment
1304000G0AACICI
|
Clobetasol propionate | Clobetasol propionate | Skin | No data available |
|
Coal tar solution 5% in Clobetasone 0.05% cream
1304000H0AACECE
|
Clobetasone butyrate (Topical) | Clobetasone butyrate | Skin | No data available |
|
Coal tar solution 6% in Betamethasone valerate 0.025% cream
1304000F0AAFNFN
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | No data available |
|
Coal tar solution 6% in Betamethasone valerate 0.1% ointment
1304000F0AADEDE
|
Betamethasone valerate (Topical) | Betamethasone valerate | Skin | No data available |
|
Coal tar solution 6% in Clobetasol 0.05% cream
1304000G0AACTCT
|
Clobetasol propionate | Clobetasol propionate | Skin | No data available |
|
Coal tar solution strong
1305020C0AAANAN
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar solution strong 1.25% / Cade oil 0.5% shampoo
1309000C0AAAAAA
|
Coal tar (Scalp) | Coal tar | Skin | No data available |
|
Coal tar solution strong 15% in Emulsifying ointment
1305020C0AAGAGA
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Coal tar solution strong 6% in Yellow soft paraffin
1305020C0AAGVGV
|
Coal tar/tar (Topical) | Tars | Skin | No data available |
|
Colestyramine 10% cream
1303000E0AAAAAA
|
Colestyramine (Antipruritic) | Colestyramine | Skin | No data available |
|
Colestyramine 5% cream
1303000E0AAABAB
|
Colestyramine (Antipruritic) | Colestyramine | Skin | No data available |
|
Colistin 19.5million unit powder vials
1310011W0AAAAAA
|
Colistin sulfate (Topical) | Polymyxins | Skin | No data available |
|
Colomycin 19.5million unit powder vials
1310011W0BBAAAA
|
Colomycin (Topical) | Polymyxins | Skin | No data available |
|
Colsor cream
131003000BLBDA0
|
Proprietary compound preparation BNF 1310030 | Other antiviral preparations | Skin | No data available |
|
Comfrey and Vitamin E balm
130201000BBHFA0
|
Proprietary compound emollients | Other emollient preparations | Skin | No data available |
|
Compound W 17% wart remover paint
1307000M0BDAAAI
|
Compound W | Salicylic acid | Skin | No data available |
|
Couvrance foundation cream rich formula SPF30
130802000BBDJA0
|
Proprietary compound preparation BNF 1308020 | Other camouflage preparations | Skin | No data available |
|
Couvrance foundation crm powdered finish formula SPF30
130802000BBDIA0
|
Proprietary compound preparation BNF 1308020 | Other camouflage preparations | Skin | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.